Evidence map›Paper›PMID 40476844›Full record

Trial reportFuture oncology (London, England)2025

A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.

Munehiro Wakabayashi, Toshiki Masuishi, Takatsugu Ogata, Fumiyasu Hanamura, Mitsuhiro Furuta, Yoshiyuki Yamamoto, Kentaro Kawakami, Hidekazu Hirano, Yosuke Kito, Naoki Izawa and 8 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  2. Article
  3. Pathogenicity ofWorld journal of clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Munehiro WakabayashiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0009-0001-8844-6845
Toshiki MasuishiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Takatsugu OgataDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Fumiyasu HanamuraDepartment of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.
Mitsuhiro FurutaDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Yoshiyuki YamamotoDepartment of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan.
Kentaro KawakamiDepartment of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan.
Hidekazu HiranoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yosuke KitoDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Naoki IzawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Naoki TakahashiDepartment of Gastroenterology, Saitama Cancer Center Hospital, Saitama, Japan.
Toshihiko MatsumotoDepartment of Medical Oncology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
Hisato KawakamiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.
Takayuki AndoThird Department of Internal Medicine, University of Toyama, Toyama, Japan.
Keiko MinashiClinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
Chiho KudoDepartment of Clinical Research Support Section, Aichi Cancer Center Hospital, Nagoya, Japan.
Kenichi YoshimuraCenter for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced gastric cancer (AGC) patients with severe peritoneal metastases (SPM), characterized by massive ascites and/or inadequate oral intake, have a poor prognosis with the median overall survival of around 7 months, even when treated with fluorouracil/l-leucovorin plus oxaliplatin (mFOLFOX6), despite being a treatment options for these patients demonstrated in the WJOG10517G study. However, these patients were excluded from pivotal Phase III trials, including the CheckMate 649 study, which demonstrated the benefit of adding nivolumab to mFOLFOX6, due to tumor-related complications. Given the lack of data on the efficacy and safety of combining nivolumab with mFOLFOX6 for AGC patients with SPM, we initiated a Phase II study to evaluate this combination. The primary endpoint was the 1-year survival rate.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPeritoneal NeoplasmsStomach NeoplasmsAdultAgedFemaleFluorouracilHumansLeucovorinMaleMiddle AgedNivolumabOrganoplatinum CompoundsTreatment OutcomeFluorouracilLeucovorinNivolumabOrganoplatinum CompoundsGastric cancerinadequate oral intakemassive ascitesmFOLFOX6 plus nivolumabsevere peritoneal metastases

Identifiers

PMID40476844
PMCPMC12239818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.